Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 13/20 | 0.65 |
| ▸ | ITGA4 | P13612 | 13/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.38 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2432807 | 1.00 | ITGB1 (0.65) | ITGB1ITGA4LMNAHDAC1HDAC6 | |
| SCHEMBL2429448 | 0.94 | ITGB1 (0.58) | ITGB1ITGA4HDAC1HDAC6 | |
| SCHEMBL2429445 | 0.94 | ITGB1 (0.58) | ITGB1ITGA4HDAC1HDAC6 | |
| SCHEMBL2433948 | 0.94 | ITGB1 (0.57) | ITGB1ITGA4HDAC1HDAC6HCRTR1 | |
| SCHEMBL2433946 | 0.94 | ITGB1 (0.57) | ITGB1ITGA4HDAC1HDAC6HCRTR1 | |
| SCHEMBL2432091 | 0.93 | ITGB1 (0.62) | ITGB1ITGA4HDAC1HDAC6 | |
| SCHEMBL2433527 | 0.91 | ITGB1 (0.54) | ITGB1ITGA4HDAC1HDAC6 | |
| SCHEMBL2433530 | 0.91 | ITGB1 (0.54) | ITGB1ITGA4HDAC1HDAC6 | |
| SCHEMBL2434117 | 0.90 | ITGB1 (0.53) | ITGB1ITGA4HDAC1HDAC6 | |
| SCHEMBL2434114 | 0.90 | ITGB1 (0.53) | ITGB1ITGA4HDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1346982-B1 | VLA-4 INHIBITORS | DAIICHI SEIYAKU CO (JP) | 2011-09-14 | — | — | EP | disclosed |
| US-7157487-B2 | Vla-4 inhibitors | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-01-02 | — | — | US | disclosed |
| US-20040110945-A1 | Vla-4 inhibitors | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-06-10 | — | — | US | disclosed |
| EP-1346982-A1 | VLA-4 INHIBITORS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-09-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110945-A1 | Vla-4 inhibitors | VCAM1, ITGA1, ITGB4 | ITGB1 5/4885ITGA4 4/4885LMNA 2852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.